title: Bimatoprost 0.03% for the Treatment of Eyebrow Hypotrichosis.
abstract: BACKGROUND
  Eyebrow loss may have substantial negative functional and social consequences.
  
  
  OBJECTIVE
  Evaluate the safety and efficacy of bimatoprost 0.03% in subjects with eyebrow hypotrichosis.
  
  
  METHODS
  This multicenter, double-masked study randomized adult females or males with eyebrow hypotrichosis to receive bimatoprost 0.03% twice (BID) or once daily (QD) or vehicle BID for 7 months. Primary endpoint was overall eyebrow fullness at Month 7. Secondary endpoints included eyebrow fullness (mm), darkness (intensity units), and subject satisfaction with treatment. Safety was also assessed.
  
  
  RESULTS
  At Month 7, the proportion of subjects with improvement was significantly higher in bimatoprost groups versus vehicle (both, p < .001). Improvements occurred in both bimatoprost groups versus vehicle after Month 1 and continued through follow-up; eyebrow fullness and darkness improved as early as Months 2 and 1, respectively (both, p < .001). Greater satisfaction was reported with bimatoprost versus vehicle at Month 2 and all subsequent time points. Overall, 38.1%, 42.4%, and 35.5% of subjects in the bimatoprost BID, QD, and vehicle groups, respectively, experienced ≥1 treatment-emergent adverse event (TEAE). Most frequent TEAEs were similar across groups. No skin or iris hyperpigmentation or conjunctival hyperemia occurred.
  
  
  CONCLUSIONS
  Bimatoprost 0.03% BID and QD is safe, well tolerated, and effective for eyebrow hypotrichosis.
authors.affiliation: *Clinical Research, Vancouver, Canada; †Surgical, Aesthetic and General Dermatology, West Palm Beach, Florida; ‡Center for Cosmetic Dermatologic Surgery, Metairie, Los Angeles; §Dermatology Consulting Services, High Point, North Carolina; ‖Division of Dermatology, University of California at Los Angeles, Los Angeles, California; ¶Goldman, Butterwick, Fitzpatrick, Groff and Fabi: Cosmetic Laser Dermatology, San Diego, California; #Peloton Advantage, Parsippany, New Jersey; **Allergan plc, Irvine, California.
authors.forename: Jean
authors.initials: J
authors.lastname: Carruthers
authors.forename: Kenneth
authors.initials: K
authors.lastname: Beer
authors.forename: Alastair
authors.initials: A
authors.lastname: Carruthers
authors.forename: William P
authors.initials: WP
authors.lastname: Coleman
authors.forename: Zoe Diana
authors.initials: ZD
authors.lastname: Draelos
authors.forename: Derek
authors.initials: D
authors.lastname: Jones
authors.forename: Mitchel P
authors.initials: MP
authors.lastname: Goldman
authors.forename: Michael L
authors.initials: ML
authors.lastname: Pucci
authors.forename: Amanda
authors.initials: A
authors.lastname: VanDenburgh
authors.forename: Emily
authors.initials: E
authors.lastname: Weng
authors.forename: Scott M
authors.initials: SM
authors.lastname: Whitcup
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000069580:Bimatoprost / Q000008:administration & dosage*; D003357:Cosmetic Techniques; D004311:Double-Blind Method; D005138:Eyebrows / Q000187:drug effects*; D005260:Female; D006801:Humans; D007039:Hypotrichosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D016896:Treatment Outcome
chemical_list: D000069580:Bimatoprost